RZLT · Rezolute, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $61.53M | $55.74M | $43.81M | $32.49M | $14.99M | $14.45M |
| SG&A | $18.37M | $14.68M | $12.18M | $9.36M | $7.91M | $6.07M |
| Total Operating Expenses | $79.89M | $70.42M | $55.99M | $41.84M | $22.89M | $20.52M |
| D&A | $31.0K | $36.0K | $30.0K | $13.0K | $13.0K | $18.0K |
| Operating Income | ($79.89M) | ($70.42M) | ($55.99M) | ($41.84M) | ($22.89M) | ($20.52M) |
| Interest Expense | - | - | - | - | $375.0K | $0 |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($74.41M) | ($68.46M) | ($51.79M) | ($41.06M) | ($20.90M) | ($20.33M) |
| EPS - Basic | ($0.98) | ($1.33) | ($1.01) | ($2.72) | - | - |
| EPS - Diluted | ($0.98) | ($1.33) | ($1.01) | ($2.72) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $94.11M | $70.40M | $16.04M | $150.41M | $41.05M | $9.96M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $5.81M | $4.90M | $3.27M | $1.13M | $1.03M | $893.0K |
| Current Assets | $171.15M | $128.65M | $104.91M | $152.10M | $41.99M | $10.52M |
| Total Assets | $175.49M | $132.74M | $123.72M | $152.42M | $42.61M | $10.96M |
| Current Liabilities | $11.91M | $9.61M | $5.20M | $2.46M | $1.97M | $3.23M |
| Long-term Debt | - | - | - | - | $13.97M | $6.14M |
| Total Liabilities | $13.36M | $11.73M | $7.55M | $2.95M | $16.51M | $3.60M |
| Stockholders' Equity | $162.13M | $121.00M | $116.17M | $149.47M | $26.10M | $7.37M |
| Retained Earnings | ($403.86M) | ($329.44M) | ($260.99M) | ($209.20M) | ($168.14M) | ($147.24M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($69.08M) | ($57.37M) | ($44.48M) | ($39.62M) | ($20.44M) | ($24.17M) |
| Investing Cash Flow | ($14.54M) | $48.70M | ($101.46M) | - | $0 | $0 |
| Financing Cash Flow | $107.33M | $63.03M | $11.57M | $148.98M | $51.53M | $22.55M |
| CapEx | - | - | $153.0K | - | - | $0 |
| Free Cash Flow | - | - | ($44.63M) | - | - | ($24.17M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.86 | - | - | 1.19 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -42.4% | -51.6% | -41.9% | -26.9% | -49.1% | -185.4% |
| Return on equity | -45.9% | -56.6% | -44.6% | -27.5% | -80.1% | -276.1% |
| Return on invested capital | - | - | - | - | -45.1% | -120.0% |
| Liquidity | ||||||
| Current ratio | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 |
| Quick ratio | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 |
| Cash ratio | 7.90 | 7.33 | 3.08 | 61.09 | 20.86 | 3.09 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.54 | 0.83 |
| Debt / Assets | - | - | - | - | 0.33 | 0.56 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -61.1x | - |
| Equity multiplier | 1.08 | 1.10 | 1.06 | 1.02 | 1.63 | 1.49 |
| Liabilities / Assets | 0.08 | 0.09 | 0.06 | 0.02 | 0.39 | 0.33 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 2.1x | 1.8x | 0.9x | 0.2x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.4% | -25.8% | -33.8% | -82.8% | -11.6% | 20.9% |
| Net income growth (YoY) | -8.7% | -32.2% | -26.1% | -96.4% | -2.8% | 33.2% |
| EPS growth (YoY) | 26.3% | -31.7% | 62.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | -57.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 34.0% | 4.2% | -22.3% | 472.7% | 254.4% | 320.4% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Rezolute against the 5 most active filers in the same SIC group.